Summary of the Conference Call Records Company Overview - **Company**: Xiansheng Pharmaceutical (先声药业) - **Industry**: Biopharmaceuticals, specifically focusing on innovative drug development for inflammatory bowel disease (IBD) Key Points and Arguments Partnership and Collaboration - On January 27, 2026, Xiansheng Pharmaceutical announced a licensing and collaboration agreement with Boehringer Ingelheim to jointly develop the preclinical dual-specific antibody SIM0709 targeting TL1A and IL-23 for the treatment of IBD [1] - Xiansheng Pharmaceutical will receive an upfront payment of €42 million, with potential milestone payments reaching up to €1.016 billion based on development, registration, and commercial success [1] Product Development and Pipeline - SIM0709 is developed from Xiansheng's multi-antibody technology platform and has shown superior efficacy in both in vitro and in vivo studies compared to the combination of two single drugs [2] - The company has 10 approved innovative drugs and over 60 projects in its R&D pipeline, with expectations to approve 2-3 new innovative drugs annually [2] - Upcoming approvals include Enlitaz (injection of rituximab β) and Xianbixin sublingual tablets in 2024, and Enzeshun (injection of suvezatamab, VEGF) and the insomnia treatment Daliresheng in 2025 [2] Business Development and Market Position - As of January 2026, Xiansheng Pharmaceutical has achieved 5 technology licensing agreements for early-stage self-developed innovative drugs, with a total potential transaction value exceeding $4.6 billion [2] - The company has successfully established its ADC (Antibody-Drug Conjugate) and TCE (T-cell Engager) platforms, with ongoing clinical pipeline advancements and business development collaborations [3] Financial Performance and Shareholder Returns - Xiansheng Pharmaceutical maintains a solid core business with high dividend payouts and shareholder returns, indicating strong R&D contributions and potential for upward elasticity [3] Additional Important Information - Over 3 million people globally are affected by inflammatory bowel disease (IBD), highlighting the significant market potential for SIM0709 and similar treatments [2] - The innovative drug matrix of Xiansheng Pharmaceutical is rich, with multiple blockbuster products expected to be approved in the near future, reinforcing the company's growth trajectory [2]